Drugs that contain Alogliptin Benzoate; Pioglitazone Hydrochloride
1. List of Oseni drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(1 year, 11 months from now) | |
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(1 year, 11 months from now) | |
| US8637079 | TAKEDA PHARMS USA | Solid preparation comprising alogliptin and pioglitazone |
Jun, 2029
(6 years from now) | |
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin
Dosage: TABLET;ORAL
OSENI family patents
12
United States
9
China
6
Japan
4
Taiwan, Province of China
3
Israel
3
Argentina
3
Korea, Republic of
2
South Africa
2
Denmark
2
Austria
2
Mexico
2
Australia
2
Hong Kong
2
Slovenia
2
Morocco
2
Norway
2
Costa Rica
2
Germany
2
Brazil
2
Croatia
2
Portugal
2
Cyprus
2
Malaysia
2
Spain
2
Poland
2
RS
2
Georgia
2
Ukraine
2
EA
2
Canada
2
New Zealand
2
European Union
1
Jordan
1
Hungary
1
Netherlands
1
Dominican Republic
1
Peru
1
Chile
1
Ecuador
1
Luxembourg
1
Tunisia
1
ME
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic